Combining talquetamab and daratumumab could create a synergy to get more from talquetamab to attack multiple myeloma. Updated results from the phase 2 TRiMM-2 study reported Saturday at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results